J&J, Achillion Could Set Six-Week Treatment Paradigm In HCV
Executive Summary
Interim Phase IIa data of a triple combination from J&J and Achillion shows 100% SVR at end of treatment with a six-week dosing regimen. No currently approved HCV therapy has such a short treatment duration.
You may also be interested in...
With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field
J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.
HCV Notes: NICE Nod To Gilead's Epclusa; Achillion, AbbVie Data Updates
The UK's health care cost-assessment body finds Gilead's newest combo, Epclusa, cost-effective in most HCV settings. J&J/Achillion now have 12-week SVR data for six-week treatment regimen, and AbbVie builds support for an eight-week regimen for Viekirax.
Gilead Faces Challenges In HCV, But Competitors Would Switch Places
Gilead Sciences Inc. may be experiencing a slowdown in therapy starts in hepatitis C, with some analysts predicting a bit of erosion in its dominant market share, but competitors Merck & Co. Inc., AbbVie Inc. and Bristol-Myers Squibb Co. still would love to have Gilead's problems.